药石科技热烈祝贺合作伙伴劲方医药在香港联交所主板挂牌上市！

Core Viewpoint - GenFleet Therapeutics successfully listed on the Hong Kong Stock Exchange on September 19, 2025, marking a significant milestone in its development and showcasing its innovative strength and growth potential [1][3]. Company Overview - GenFleet Therapeutics is the first new drug company in the 18A sector to have a listed product and authorized revenue during its IPO phase. Its product, Fluorazepine, is the first KRAS G12C inhibitor approved in China and the third globally [3][7]. - The company has completed multiple licensing transactions with domestic and international listed companies, including Innovent Biologics and Verastem Oncology, since 2021, generating authorized revenue [3][4]. Product Pipeline - GenFleet's product pipeline includes several original products that are leading in development speed both domestically and internationally. Fluorazepine received priority review qualification for domestic listing after six years of development [4]. - The company is advancing GFH375, an oral KRAS G12D inhibitor, which is in the first tier of development for treating pancreatic cancer and non-small cell lung cancer (NSCLC) [4]. - The pipeline also features GFH276, a pan-RAS inhibitor, which has entered Phase I/II clinical trials in China, positioning it among the leading candidates in the domestic market [4]. Innovative Therapies - GenFleet has introduced multiple globally innovative dual-target therapies, addressing significant clinical needs in markets such as pancreatic cancer and NSCLC. The KROCUS study presents the first global KRAS+EGFR first-line treatment for NSCLC [5]. - GFS202A is the first clinical-stage dual antibody therapy targeting GDF15/IL-6 for cachexia, with potential applications in chronic diseases like heart failure and chronic kidney disease [5]. - The FAScon platform represents a novel antibody-drug conjugate (ADC) approach, combining functional antibodies with targeted drug delivery, aiming to revolutionize traditional ADC development [5]. Collaboration and Support - PharmaBlock Technology plays a crucial role in supporting GenFleet's core pipeline through its comprehensive small molecule drug development services, including rapid synthesis of preclinical compounds and customized synthesis for clinical production [6]. - The collaboration emphasizes sustainable development through low-carbon production technologies and green chemistry practices, enhancing production efficiency while minimizing environmental impact [6]. Recognition and Achievements - GenFleet has received several accolades, including the national-level "Little Giant" designation and recognition as a high-tech enterprise, reflecting its innovative capabilities and growth trajectory [8]. - The company has established a robust commercial cooperation network, engaging in strategic licensing agreements and global clinical collaborations with various domestic and international firms [8].